PASG — Passage BIO, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1787297 ·
Last close
$5.81
Market Cap
$18.64M
52W High
$12.05
52W Low
$3.93
ADV30
55,187
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -8,880,000 | -7,559,000 | 36,462,000 | 33,336,000 | 24,710,000 |
| Dec 2025 | 0 | — | -10,340,000 | -12,983,000 | 62,281,000 | 46,303,000 | 43,526,000 |
| Sep 2025 | 0 | — | -8,655,000 | -7,749,000 | 74,160,000 | 52,773,000 | 43,040,000 |
| Jun 2025 | 0 | — | -10,334,000 | -9,385,000 | 79,198,000 | 57,626,000 | 40,940,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,649,000
Investing CF
$605,000
Financing CF
$23,000
CapEx
$-14,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.63
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-712,316,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-38,209,000
Pretax Income TTM
$-37,676,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -43,151,000 | -45,522,000 | 62,281,000 | 43,526,000 | — | -31,509,000 |
| Dec 2024 | 0 | -65,167,000 | -64,767,000 | 102,412,000 | 41,151,000 | — | -47,956,000 |
| Dec 2023 | 0 | -102,999,000 | -102,062,000 | 150,545,000 | 39,262,000 | — | -78,264,000 |
| Dec 2022 | 0 | -135,394,000 | -136,125,000 | 243,549,000 | 42,183,000 | — | -118,210,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-10.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | $18.27M | $0.93 | — |
| CRIS | CURIS INC | $16.37M | $0.42 | — |
| CVM | CEL SCI CORP | $15.65M | $1.08 | — |
| PLUR | Pluri Inc. | $24.49M | $2.27 | — |
| DYAI | DYADIC INTERNATIONAL INC | $24.78M | $0.68 | — |
News headlines (Yahoo Finance, 1h cache)
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
2026-05-20 12:35 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-04-21 19:57 · Yahoo
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
2026-04-21 18:20 · Yahoo
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
2026-04-21 15:46 · Yahoo
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
2026-04-20 11:00 · Yahoo
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
2026-03-03 12:00 · Yahoo
Passage Bio to Participate in Upcoming Investor Conferences
2026-02-19 12:00 · Yahoo
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
2025-11-10 21:15 · Yahoo
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
2025-11-05 12:00 · Yahoo
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
2025-10-14 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.